September 28, 2025 a 05:01 pm
TMO: Analysts Ratings - Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. continues to demonstrate a strong market presence, particularly in the life sciences sector. Recent analyst ratings indicate a stable outlook with a pronounced inclination towards "Buy" recommendations. This sentiment reflects confidence in the company's expansive product lines and global reach.
Historical Stock Grades
The analyst ratings for Thermo Fisher Scientific as of September 2025 show a predominance of positive sentiment, with zero "Sell" or "Strong Sell" recommendations. With 7 "Strong Buy" and 16 "Buy" ratings, the stable commitment from analysts is evident.
| Recommendation | Count | Score Bar |
|---|---|---|
| Strong Buy | 7 | |
| Buy | 16 | |
| Hold | 7 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
- Over the past months, the "Strong Buy" and "Buy" ratings have remained relatively stable, highlighting consistent confidence in the stock.
- The total number of recommendations has shown minor fluctuations, with some months witnessing a slight increase in "Hold" ratings.
- The trend suggests a persistent preference towards "Buy", although the relative stability in the "Hold" category indicates some caution.
Percentage Trends
- Recent months have observed a slight decrease in "Strong Buy" recommendations, complemented by stable "Buy" ratings.
- The percentage of "Hold" ratings has shown a mild increase, reflecting a cautious market sentiment.
- This shift suggests a gradual transition towards conservatism in analyst opinions, amidst a robust overarching positive sentiment.
- Notable is the consistent absence of "Sell" and "Strong Sell" recommendations, emphasizing long-term confidence.
Latest Analyst Recommendations
The most recent analyst actions indicate a solid endorsement of Thermo Fisher Scientific's market standing, with upgraded recommendations and maintained ratings.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-09-11 | Overweight | Equal Weight | Barclays |
| 2025-07-24 | Overweight | Overweight | Wells Fargo |
| 2025-07-24 | Neutral | Neutral | UBS |
| 2025-07-24 | Equal Weight | Equal Weight | Barclays |
| 2025-07-24 | Outperform | Outperform | Raymond James |
Analyst Recommendations with Change of Opinion
Significant changes in analyst opinions are evident, with several upgrades and downgrades, reflecting a dynamic reassessment of the company's prospects.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-09-11 | Overweight | Equal Weight | Barclays |
| 2025-07-11 | Sector Outperform | Sector Perform | Scotiabank |
| 2025-07-09 | Neutral | Buy | UBS |
| 2024-01-24 | Equal Weight | Overweight | Barclays |
| 2024-01-08 | Market Perform | Outperform | Bernstein |
Interpretation
The market sentiment surrounding Thermo Fisher Scientific remains broadly positive, underpinned by a strong contingent of "Buy" recommendations. Notably, the shifting analyst ratings, especially the upgrades, reflect an underlying confidence in its expanding market footprint. Despite some downgrades, the absence of negative ratings signifies a prevailing trust in the company's strategic direction. Overall, the analyst community appears to maintain a balanced optimism towards TMO.
Conclusion
Thermo Fisher Scientific Inc. presents a compelling investment case, buttressed by consistent "Buy" recommendations. The steady market confidence points towards promising growth prospects in life sciences and diagnostics. However, the subtle increase in "Hold" ratings signals potential cautionary stances from certain analysts. As such, while investment opportunities abound, stakeholders should remain vigilant to market shifts. Overall, TMO's strategic direction and expansive market strategies position it favorably for future advancements.